ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 04 2021 - 6:30AM
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage
oncology company focused on developing treatments that address
mechanisms of therapeutic resistance, today announced that Jacob
Chacko, M.D., chief executive officer, will present a company
overview at the 39th Annual J.P. Morgan Healthcare Conference on
Tuesday, January 12, 2021 at 12:40 p.m. PT.
A live webcast will be available through the investor section of
the company’s website at www.oricpharma.com. A replay of the
webcast will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.ORIC
Pharmaceuticals is a clinical stage biopharmaceutical company
dedicated to improving patients’ lives
by Overcoming Resistance In Cancer. ORIC’s lead
product candidate, ORIC-101, is a potent and selective small
molecule antagonist of the glucocorticoid receptor, which has been
linked to resistance to multiple classes of cancer therapeutics
across a variety of solid tumors. ORIC-101 is currently in two
separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi
(enzalutamide) in metastatic prostate cancer and (2) Abraxane
(nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s
other product candidates include (1) ORIC-533, an orally
bioavailable small molecule inhibitor of CD73, a key node in the
adenosine pathway believed to play a central role in resistance to
chemotherapy- and immunotherapy-based treatment regimens, (2)
ORIC-944, an allosteric inhibitor of the polycomb repressive
complex 2 (PRC2) via the EED subunit, being developed for prostate
cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to
selectively target EGFR and HER2 with high potency against exon 20
insertion mutations, being developed across multiple genetically
defined cancers. Beyond these four product candidates, ORIC is also
developing multiple precision medicines targeting other hallmark
cancer resistance mechanisms. ORIC has offices in South San
Francisco and San Diego, California. For more information, please
go to www.oricpharma.com.
Contact:Dominic Piscitelli, Chief Financial
Officer
dominic.piscitelli@oricpharma.com info@oricpharma.com
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Jul 2023 to Jul 2024